Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.

By J. Sosman, Kevin B. Kim, L. Schuchter, R. Gonzalez, A. Pavlick, J. Weber, G. McArthur, Thomas E. Hutson, S. Moschos, K. Flaherty and 15 more. New England Journal of Medicine, 2012

2,135 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/aee468f8e6236ab3c4c8365e74572cc95613fbe8

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

1. Feng Zhang
2. Neville E. Sanjana
3. Ophir Shalem
4. David A. Scott
5. R. Salazar
6. A. Bardelli
7. Benjamin L. Ebert
8. Tarjei S. Mikkelsen

In Oncology

1. D. Pardoll
2. Padmanee Sharma
3. James P. Allison
4. S. Topalian
5. Janis Taube
6. F. Hodi
7. K. Flaherty
8. J. Wargo

Citations in the corpus

• A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer (2019, background): “Advanced melanoma BRAF V600 Vemurafenib (PLX4032) versus facarbazine chemotherapy BRAF and methylation agent Phase 3 trial (NCT01006980) 2011–2016, completed High rate of response for patient with activating BRAF mutations [119]”
• Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. (2014, neutral): “(%) 56/210 (27) 61/211 (29) 117/421 (28)”
• Overcoming intrinsic multi-drug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells (2013, background): “…factors, including the cancer type and stage, the sequence of oncogenes activated, which can directly influence mitochondrial metabolism, the current microenvironmental context, and also the rate of cell proliferation (Berridge et al., 2010; Jose et al., 2011; Vander Heiden et al., 2009).”
• Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells (2014, background): “is short-lived and resistance develops in a majority of cases (6-8).”
• ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “Also, BRAF V600E-mutated melanomas are sensitive to the BRAF-mutant inhibitor vemurafenib [69], but BRAF-mutated CRCs are not as sensitive [70, 71].”